bromfenac (xibrom) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bromfenac is a topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia and vision blurred.   NCATS

Chemistry

  • SMILES: Nc1c(CC(=O)O)cccc1C(=O)c2ccc(Br)cc2
  • InChIKey: ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
  • Mol. Mass: 334.17
  • ALogP: 2.89
  • ChEMBL Molecules:
    bromfenac  
    bromfenac sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$35.6780 - $95.6778
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-amino-3-(4-bromobenzoyl)benzeneacetic acid | [2-amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid | ahr-10282 | ahr-10282b | bromday | bromefenac | bromfenac | bromfenaco | bromfenac sodium | bromfenac sodium hydrate | bromfenac sodium sesquihydrate | bromfenacum | duract | isv 101 | pro-155 | prolensa | sodium bromfenac | wyeth brand of sodium bromfenac | xibrom | yellox

Organizations (57)

Research & Development (41)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (24)

Approved Indications (2)


 

Inflammation (approved 2013)

Pain (approved 2013)

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

Cataract (Phase 4)

Conjunctivitis, Allergic (Phase 3)

Diabetes Mellitus (Phase 3)

Dry Eye Syndromes (Phase 4)

Exfoliation Syndrome (Phase 4)

Eye Diseases (Phase 3)

Familial Exudative Vitreoretinopathies (Phase 2)

General Surgery (Phase 4)

Glaucoma (Phase 4)

Inflammation (Phase 4)

Intraocular Pressure (Phase 4)

Intravitreal Injections (Phase 4)

Lens Diseases (Phase 3)

Macular Degeneration (Phase 2)

Macular Edema (Phase 4)

Myopia (Phase 4)

Pain (Phase 4)

Postoperative Complications (Phase 3)

Presbyopia (Phase 1)

Pseudophakia (Phase 4)

Pterygium (Phase 4)

Retinal Diseases (Phase 4)

Vision, Ocular (Phase 4)

Vitrectomy (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 51
  • # of Trial Organizations: 41

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue